In a follow up study, they determined that elimination of CD8+ T cells in a CML model led to disease progression and that IL-7 secreted by CML helped maintain a CTL response, leading to stable disease as it is characteristic of chronic phase CML (41). The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.